Pantoprazol Reiwa Healthcare (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Reiwa Healthcare, is a proton pump inhibitor presented as a strength/form for oral use. It reduces stomach acid production and is used to treat acid‑related conditions such as gastro‑oesophageal reflux disease and peptic ulcer disease in adults. GNH USA supplies Pantoprazol Reiwa Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Pantoprazol Reiwa Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related gastrointestinal conditions: - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of erosive esophagitis. - Erosive oesophagitis: heals damage to the esophageal lining caused by acid reflux. - Peptic ulcer disease: supports ulcer healing and reduces recurrence risk. - Zollinger‑Ellison syndrome: controls excessive gastric acid production associated with this rare endocrine disorder.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: usually self‑limiting. - Nausea: occasional and transient. - Abdominal pain: mild discomfort. - Flatulence: excess gas. - Constipation: infrequent.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): requires immediate medical attention. - Clostridioides difficile infection: may present with persistent diarrhea. - Low magnesium levels (hypomagnesemia): can cause muscle cramps or cardiac arrhythmia. - Bone fractures: associated with long‑term use. - Liver enzyme elevation: indicates possible hepatic involvement. - Acute interstitial nephritis: rare kidney inflammation.

Pantoprazole should be used with consideration of several safety aspects.

- Assess risk for Clostridioides difficile infection: monitor patients with recent antibiotic use. - Evaluate renal function before initiation and periodically during treatment. - Review potential drug interactions with warfar and antiplatelet agents. - Use caution in patients with severe liver disease or hepatic impairment. - Store at below 25°C: keep the tablet in the original pres‑

The             "  "   "  " ...  "   "" …  ");

"  " "" "  t  " " "" " """ "" """ "" " """  t "" "" "

"  t"" ""